Can a Two-Drug attack outsmart resistant breast cancer?
NCT ID NCT05575804
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This trial is testing whether a new antibody-drug conjugate called GQ1001, when combined with the oral drug pyrotinib, can safely shrink tumors in people with HER2-positive metastatic breast cancer that has stopped responding to earlier anti-HER2 treatments. The study enrolls about 32 adults and will first find the safest dose, then measure how well the combination works. It aims to offer a potential new option for a hard-to-treat form of breast cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GQ1001 (an antibody-drug conjugate targeting HER2) combined with pyrotinib (a tyrosine kinase inhibitor)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with HER2-positive breast cancer that has stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial with only 32 participants, so results may not apply broadly. Side effects from the drug combination could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/ METASTATIC HER-2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••